Last reviewed · How we verify
CD-LD IR
CD-LD IR is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD).
CD-LD IR is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD). Used for Attention deficit hyperactivity disorder (ADHD).
At a glance
| Generic name | CD-LD IR |
|---|---|
| Also known as | Sinemet, Carbidopa-levodopa immediate-release tablets |
| Sponsor | Impax Laboratories, LLC |
| Drug class | Central nervous system stimulant |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
It works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which help to improve focus and impulse control. This medication is not a controlled substance, but it can be habit-forming if taken for extended periods or in high doses.
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
Common side effects
- Insomnia
- Headache
- Nausea
- Dizziness
- Anxiety
Key clinical trials
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa (PHASE2)
- Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD-LD IR CI brief — competitive landscape report
- CD-LD IR updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI